media – Page 426 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

COVID-19 lockdowns increase the number of polio cases in Pakistan

A spike in the number of polio cases in Pakistan — the last refuge of the virus in the world along with neighbouring Afghanistan — is being attributed by health experts to disruption in vaccination services caused by lockdowns and restrictions against spread of the COVID-19 pandemic. “The increase in polio cases could result in the global export of infections and healthcare authorities must intensify efforts to track and vaccinate unvaccinated children, says Misbahud Din, researcher in molecular biology and immunology at Quaid-i-Azam University, Islamabad and lead author of a study, published October online in Public Health, on polio vaccination disruptions due to COVID-19 in Pakistan. Din tells SciDev.Net that “80 cases of wild polio virus (WPV) and 64 cases of circulating vaccine-derived poliovirus (cVDPV) have been reported in 2020”. According to the study, around 40 million children missed polio vaccination after Pakistan, on 26 March, suspended a mass vaccination programme being carried ...
- Source: drugdu
- 222
- November 8, 2020
Covid-19
Rapid rise in CRP levels predicts COVID-19 outcomes

Predicting the course of a COVID-19 patient’s disease after hospital admission is essential to improving treatment. Brigham and Women’s Hospital researchers analyzed patients’ levels of inflammation, known to be associated with severity of illness, by looking at C-reactive protein (CRP) trends in 100 COVID-19 patients admitted to the hospital. They found that a rapid rise in CRP levels during the first 48-to-72 hours of hospitalization was predictive of subsequent respiratory deterioration and intubation, while steadier CRP levels were observed in patients whose condition remained stable. Findings were published in Cell Reports Medicine. We realized that whereas a single CRP lab value from hospital admission wasn’t very practical as a predictor of who might get sicker, tracking the rate of change from Day 1 to Day 2 or 3 was a very powerful and very clinically predictive test. Even though all of these patients looked clinically similar upon admission, as early as ...
- Source: drugdu
- 350
- November 7, 2020
Covid
Fujifilm acquisition of Hitachi diagnostic imaging business delayed by COVID-19

Fujifilm Corporation’s planned $1.63 billion acquisition of Hitachi’s diagnostic imaging business has been put on hold in the midst of the ongoing COVID-19 pandemic. The Japanese healthcare giants, which began discussing the deal back in December, were aiming to complete the acquisition some time in July. Fujifilm, however, now says that “delays in some of the preparations” brought on by the spread of the virus have changed the completion schedule and that both parties will need more time to hammer out and finalize the details. “Due to the spread of CIVD19 globally, preparations for regulatory laws related to matters and clearance for anti-monopoly have been delayed. Government offices, legal offices and others impacted by lock downs and stay at home measures have slowed these activities,” Dave Wilson, director of communications for Hitachi Healthcare Americas, told HCB News. Fujifilm has delayed a planned acquisition of Hitachi’s diagnostic imaging-related business due to the ...
- Source: drugdu
- 309
- November 6, 2020
Covid-19
Argentina agrees to buy 25 million doses of Russia’s Covid-19 vaccine

President Fernández reveals in interview with Russian news agency that government will receive initial 10 million doses of Sputnik V vaccine by as early as December, should it clear clinical trials. resident Alberto Fernández said Monday that Argentina has accepted a proposal from Russia to buy an initial 10 million doses of its experimental Covid-19 vaccine, with delivery expected before the end of the year. The vaccine, which is given in two parts, could even arrive as early as next month provided clinical trials are successful, the president said in an interview with a Russian news agency. If successful, another 15 million doses could arrive in January, he added. The news comes just days after Perfil journalist Rosario Ayerdi revealed that Health Access Secretary Carla Vizzotti had travelled to Russia on October 17 on a fact-finding mission to learn more about the Russian vaccine, known as Sputnik V. Fernández confirmed Vizzotti’s ...
- Source: drugdu
- 301
- November 5, 2020
Covid-19 vaccine
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer

Only HER2-directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that offer significant advances over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, will be during the first quarter of 2021. There are more than 27,000 new cases of gastric cancer in the US each year, of which approximately one in five are HER2 positive.1,2 For patients with metastatic gastric cancer who progress ...
- Source: drugdu
- 319
- November 4, 2020
gastric cancer
Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1

Abstract Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, has greatly affected clinical outcomes in non-small cell lung cancer (NSCLC) patients. The long noncoding RNAs (lncRNAs) are known to regulate tumorigenesis and cancer progression, but their contributions to NSCLC gefitinib resistance remain poorly understood. In this study, by analyzing the differentially expressed lncRNAs in gefitinib-resistant cells and gefitinib-sensitive cells in the National Institute of Health GEO dataset, we found that lncRNA CASC9 expression was upregulated, and this was also verified in resistant tissues. Gain and loss of function studies showed that CASC9 inhibition restored gefitinib sensitivity both in vitro and in vivo, whereas CASC9 overexpression promoted gefitinib resistance. Mechanistically, CASC9 repressed the tumor suppressor DUSP1 by recruiting histone methyltransferase EZH2, thereby increasing the resistance to gefitinib. Furthermore, ectopic expression of DUSP1 increased gefitinib sensitivity by inactivating the ERK pathway. Our results highlight the essential role ...
- Source: drugdu
- 442
- November 3, 2020
RNA CASC9
Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

By Ludwig Burger FRANKFURT (Reuters) – Bayer <BAYGn.DE> agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses. Germany’s Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements, it said on Monday. The North Carolina-based takeover target, also known as AskBio, is trying to use the harmless adeno-associated virus as a delivery device to bring genetic repair kits against a range of diseases into the body.Drugs and farming pesticides maker Bayer needs to upgrade its drug development pipeline amid a weaker outlook for agricultural sales and as it seeks to finalise an $11 billion settlement over claims its Roundup weedkiller causes cancer. Among AskBio’s most advanced projects are early tests on volunteers of prospective treatments against Pompe disease – a ...
- Source: drugdu
- 284
- November 2, 2020
Gene therapy
Researchers reveal discovery of new cancer drug fadraciclib

by Institute of Cancer Research Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumors. The drug, called fadraciclib, was jointly discovered by scientists at The Institute of Cancer Research, London, in collaboration with the company Cyclacel. It is already being tested in early clinical trials targeting select hematological malignancies and solid tumors. In a new publication in the journal PLOS One, a team of scientists from Cyclacel and the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR) describe the discovery of fadraciclib, formerly known as CYC065, and describe its mechanism of action and therapeutic properties. Fadraciclib is a leading dual inhibitor of two cancer-driving proteins from the cyclin-dependent kinase (CDK) family, CDK2 and CDK9. CDK2/9 inhibitor It was designed by improving the chemical ...
- Source: drugdu
- 269
- November 1, 2020
fadraciclib
Argentina to co-produce coronavirus vaccine with Mexico

President Alberto Fernández confirms Argentina and Mexico will co-produce millions of doses of a coronavirus vaccine developed by scientists at the University of Oxford and Swedish-British pharma firm AstraZeneca. President Alberto Fernández has announced that Argentina and Mexico will co-produce millions of doses of a coronavirus vaccine developed by the AstraZeneca pharmaceutical firm and scientists at the University of Oxford, with it potentially reaching citizens across Latin America in the first quarter of next year. The Peronist leader, speaking at a press conference at the Olivos presidential residence on Wednesday, said that the two countries would be in charge of the “Latin American production” and distribution of a vaccine created by the prestigious British university and Swedish-British pharmaceutical group. Argentina will be in charge of producing “the active substance,” said Fernández, with Mexico finishing “production and packaging.” He said that the country “could be in a position to vaccinate” by the ...
- Source: drugdu
- 151
- October 31, 2020
Autoantibody order, timing predict genetically at-risk children most likely to get type 1 diabetes

by University of South Florida Children with multiple islet autoantibodies—biological markers of autoimmunity—are more likely to progress to symptomatic type 1 diabetes (T1D) than those who remain positive for a single autoantibody. Now, new findings from The Environmental Determinants of Diabetes in the Young (TEDDY) study in the U.S. and Europe show that detailed information about the order, timing and type of autoantibodies appearing after the first autoantibody can significantly improve prediction of which children are most likely to progress to type 1 diabetes more rapidly. The TEDDY analysis was published in the September 2020 issue of Diabetes Care. “A better understanding of distinct autoantibody spreading is important, because it will allow us to identify at-risk children earlier in the disease process,” said the study’s lead author Kendra Vehik, Ph.D., a professor of epidemiology at the University of South Florida Health (USF Health) Morsani College of Medicine’s Health Informatics ...
- Source: drugdu
- 521
- October 30, 2020
diabetes

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.